Vicore Pharma Holding AB
STO:VICO

Watchlist Manager
Vicore Pharma Holding AB Logo
Vicore Pharma Holding AB
STO:VICO
Watchlist
Price: 6.8 SEK -2.02% Market Closed
Market Cap: 1.6B SEK

Wall Street
Price Targets

VICO Price Targets Summary
Vicore Pharma Holding AB

Wall Street analysts forecast VICO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for VICO is 31.17 SEK with a low forecast of 15.15 SEK and a high forecast of 40.86 SEK.

Lowest
Price Target
15.15 SEK
123% Upside
Average
Price Target
31.17 SEK
358% Upside
Highest
Price Target
40.86 SEK
501% Upside
Vicore Pharma Holding AB Competitors:
Price Targets
QNCX
Quince Therapeutics Inc
496% Upside
PEB
Pacific Edge Ltd
51% Downside
002007
Hualan Biological Engineering Inc
26% Upside
300142
Walvax Biotechnology Co Ltd
3% Downside
603087
Gan & Lee Pharmaceuticals
36% Upside
6160
Beigene Ltd
41% Upside
GRAL
Grail Inc
8% Downside
688366
Shanghai Haohai Biological Technology Co Ltd
21% Upside

Revenue
Forecast

Revenue Estimate
Vicore Pharma Holding AB

For the last 8 years the compound annual growth rate for Vicore Pharma Holding AB's revenue is 83%. The projected CAGR for the next 3 years is -6%.

83%
Past Growth
-6%
Estimated Growth
Estimates Accuracy
-16%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Vicore Pharma Holding AB

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Net Income
Forecast

Net Income Estimate
Vicore Pharma Holding AB

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-70%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is VICO's stock price target?
Price Target
31.17 SEK

According to Wall Street analysts, the average 1-year price target for VICO is 31.17 SEK with a low forecast of 15.15 SEK and a high forecast of 40.86 SEK.

What is Vicore Pharma Holding AB's Revenue forecast?
Projected CAGR
-6%

For the last 8 years the compound annual growth rate for Vicore Pharma Holding AB's revenue is 83%. The projected CAGR for the next 3 years is -6%.

Back to Top